This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Reliv International Introduces GlucAffect(R) In The Philippines, Malaysia And Singapore

CHESTERFIELD, Mo., March 17 /PRNewswire-FirstCall/ -- Reliv International, Inc. (Nasdaq: RELV), a nutrition and direct selling company, recently introduced its blood-sugar management product, GlucAffect®, in Singapore, Malaysia and the Philippines.  

With its introduction into these Asian markets, GlucAffect is now available from Reliv independent distributors in 11 of Reliv's 15 markets. Between 12 and 19 percent of the Asian population is affected by metabolic syndrome, according to a study led by D.D. Morales.

A clinical study published in the journal Phytotherapy Research found that GlucAffect significantly reduced blood glucose levels and helped control weight in study participants.

"We believe the study results of GlucAffect represent a significant development," said Dr. Carl Hastings, vice chairman and chief scientific officer of Reliv, "because nutritional science increasingly is seen as a complement to traditional care and prescriptive remedies for metabolic syndrome."

GlucAffect, a powdered supplement consumed by mixing it with water or other liquids, has a unique combination of innovative ingredients.  Hastings said, "Ingredients were carefully selected based upon research, extensive testing, processes and controls instituted by Reliv's team of nutritional scientists."

The clinical study included 50 overweight individuals who had pre-diabetic glucose levels prior to the study.  Subjects taking GlucAffect lowered their fasting blood glucose by an average of 30 percent and they lost an average of 16 pounds.  Subjects in the control group reported a marginal decline in blood glucose levels and no significant weight loss.  

The study was conducted at Gabriele D'Annunzio University in Chieti-Pescara, Italy.

The participants consumed GlucAffect or a placebo four times a day for six days a week, participated in an exercise program and ate a healthy diet.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RELV $0.68 0.00%
AAPL $110.38 0.00%
FB $92.07 0.00%
GOOG $626.91 0.00%
TSLA $247.57 0.00%


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs